Researchers conducted a prospective study focusing on asymptomatic patients with diabetes to investigate the prevalence and prognostic significance of unrecognized MI.
Intense antihypertensive treatment with perindopril-indapamide may reduce all-cause mortality and major vascular events in type 2 diabetes, irrespective of baseline blood pressure or 10-year risk for atherosclerotic cardiovascular disease.
Treatment with linagliptin in patients with type 2 diabetes and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events.
The cardiovascular and renal effects of treatment with canagliflozin in patients with type 2 diabetes are more prominent in patients not taking metformin compared with patients treated with canagliflozin as an add-on to metformin.
Glucose screening during pregnancy can predict future cardiovascular (CV) risk in women with and without gestational diabetes, according to study results published in The Lancet Diabetes & Endocrinology. CV risk was found to be higher with abnormal glucose screening tests, but there was also increased CV risk in women with glucose concentrations at the upper…
Investigators examined the safety and lipid‐lowering efficacy of evolocumab combined with atorvastatin in patients with type 2 diabetes and hyperlipidemia or mixed dyslipidemia.
Parathyroidectomy may have a potential beneficial effect on lipid profiles and decrease cardiovascular risk in patients with primary hyperparathyroidism.
Bempedoic acid, an investigational ATP citrate lyase inhibitor, might safely lower low-density lipoprotein cholesterol levels when added to statin therapy.
High ankle-brachial index, a marker of arterial stiffness, may be used to assess the risk for cardiovascular autonomic neuropathy in type 1 diabetes.
Docosahexaenoic acid supplements given to mothers during pregnancy may lower systolic and diastolic blood pressure associated with overweight and obesity in their children.
